Treatment of steroid-refractory acute GVHD
| Organ with predominant GVHD manifestation . | Secondary therapy . |
|---|---|
| Skin | ATG (thymoglobulin, ATGAM); denileukin diftitox; monoclonal antibodies (anti-CD25, anti-CD3, anti-CD52); phototherapy (PUVA, ECP); chemotherapy (MMF, calcineurin inhibitors, pentostatin, sirolimus) |
| Liver | ATG; denileukin diftitox; monoclonal antibodies; chemotherapy (sirolimus, pentostatin, calcineurin inhibitors); phototherapy |
| Intestinal tract | “Nonabsorbable” steroids (beclomethasone, budesonide); ATG; TNFα blockade (infliximab, etanercept); chemotherapy (sirolimus, pentostatin, calcineurin inhibitors); mesenchymal “stem” cells; octreotide |
| Organ with predominant GVHD manifestation . | Secondary therapy . |
|---|---|
| Skin | ATG (thymoglobulin, ATGAM); denileukin diftitox; monoclonal antibodies (anti-CD25, anti-CD3, anti-CD52); phototherapy (PUVA, ECP); chemotherapy (MMF, calcineurin inhibitors, pentostatin, sirolimus) |
| Liver | ATG; denileukin diftitox; monoclonal antibodies; chemotherapy (sirolimus, pentostatin, calcineurin inhibitors); phototherapy |
| Intestinal tract | “Nonabsorbable” steroids (beclomethasone, budesonide); ATG; TNFα blockade (infliximab, etanercept); chemotherapy (sirolimus, pentostatin, calcineurin inhibitors); mesenchymal “stem” cells; octreotide |